There are currently 1308 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Emory University Hospital/Winship Cancer Institute and Children's Health Care of Atlanta. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT01042379
Recruiting
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia
Conditions: Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Register for Updates
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
NCT05866302
Recruiting
The study will have two separate patient cohorts: Cohort 1 will include patients with newly diagnosed chronic graft versus host disease (GVHD), whereas cohort 2 will include patients with newly diagnosed chronic lung disease (CLD). For cohort 1, the primary objective will be to characterize PRM metrics at the onset of chronic GVHD and determine if a PRM signature is present that will predict 1-year CLD free survival. For cohort 2, the primary objective will focus on characterizing PRM at the ons... Read More
Gender:
ALL
Ages:
36 months and above
Trial Updated:
10/15/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Chronic Lung Disease, Hematopoietic Cell Transplantation, Graft Versus Host Disease
Register for Updates
Disrupting Fear-based Memory Consolidation
NCT05560113
Recruiting
This project represents a unique collaborative opportunity to pursue the essential proof-of-principle demonstration that non-invasive interference of sensory cortical memory consolidation shortly after an emotional experience can attenuate the cued fear response and potentially reduce the risk of developing post-traumatic stress disorder (PTSD). If successful, the study results would anchor a potential advance in the treatment of patients after a traumatic event and seed future animal and clinic... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/11/2024
Locations: Emory Rehabilitation Hospital, Atlanta, Georgia +1 locations
Conditions: Post-Traumatic Stress Disorder
Register for Updates
Spatial-Motor Stroke-Rehab Study
NCT06053320
Recruiting
The purpose of this study is to understand how prism adaptation training with and without electrical stimulation changes visuospatial behavior, motor system neurophysiology, and walking dysfunction.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
10/11/2024
Locations: Emory Rehabilitation Hospital, Atlanta, Georgia +2 locations
Conditions: Spatial Neglect, Stroke
Register for Updates
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer
NCT04851613
Recruiting
Study LAE205INT3101 is a Phase Ib/III study to evaluate the efficacy and safety of the combination therapy with afuresertib plus fulvestrant (afuresertib/placebo plus fulvestrant in Phase III) in patients with HR+/HER2- breast cancer who have failed 1 to 2 prior lines of endocrine therapy, and/or CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 chemotherapy) as described in the inclusion criteria.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Piedmont Cancer Institute, Atlanta, Georgia
Conditions: Breast Cancer
Register for Updates
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
NCT06100276
Recruiting
This is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate the safety, tolerability, and exploratory efficacy of intrathecally administered gene therapy AMT-162. AMT-162-001 is a Phase 1/2, multi-center, single ascending dose study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants with Generalized Anxiety Disorder (GAD)
NCT06051721
Recruiting
The purpose of this proof-of-concept trial is to examine the safety, tolerability, and pharmacokinetics (PK), and preliminary clinical efficacy of CYB004 participants with GAD.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/08/2024
Locations: CenExel ACMR, Atlanta, Georgia
Conditions: Generalized Anxiety Disorder
Register for Updates
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
NCT03858205
Recruiting
This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiatio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Bone Pain, Metastatic Malignant Neoplasm in the Bone, Plasma Cell Myeloma
Register for Updates
First in Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients with Superficial Femoral Artery Disease And/or Proximal Popliteal Artery Disease
NCT06410313
Recruiting
This is a prospective, open label, multicenter, single arm, first in human clinical study. Patients with infra-inguinal peripheral arterial disease appropriate for treatment with a femoro-popliteal stent will be enrolled. The patients will be treated with the ChampioNIR Stent System. All implanted patients will be followed up at 30 days and 6, 12, 24 and 36 months. The follow-up visits will include patency evaluation by duplex ultrasound
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/04/2024
Locations: Piedmont Healthcare, Inc., Atlanta, Georgia
Conditions: Superficial Femoral Artery Stenosis, Popliteal Artery Stenosis
Register for Updates
Childhood Cancer Predisposition Study (CCPS)
NCT04511806
Recruiting
The Childhood Cancer Predisposition Study (CCPS) is a multi-center, longitudinal, observational study that will collect clinical and biological data and specimens from children with a cancer predisposition syndromes (CPS) and their relatives. The central hypothesis is that studying individuals at high risk for childhood cancer creates a unique opportunity for improving the understanding of carcinogenesis, tumor surveillance, early detection, and cancer prevention, which will collectively contri... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/03/2024
Locations: Children's Healthcare of Atlanta (CHOA), Atlanta, Georgia
Conditions: Pediatric Cancer
Register for Updates
Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study
NCT06503900
Recruiting
This study is a prospective, randomized clinical trial. During this study,pregnant participants will be randomly assigned to receive IIV and mRNA COVID-19 vaccine either simultaneously or sequentially (7-14 days apart). All participants will receive an mRNA COVID-19 vaccine at Visit 1 (Day 1). Solicited local and systemic symptoms of reactogenicity will be assessed on day of visit for Visits 1 and 2 and daily during the 6 days following each visit using either electronic or paper symptoms diari... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/02/2024
Locations: Emory University, Atlanta, Georgia +1 locations
Conditions: Birth Outcomes, Safety, Adverse Event Following Immunization
Register for Updates
Daily Doxycycline to Inform Sexually Transmitted Infection Prophylaxis Regimens
NCT06545656
Recruiting
The goal of this project is to collect data regarding the concentrations of doxycycline in mucosal tissues after daily dosing for 7 days in people assigned male sex at birth (AMAB) and assigned female sex at birth (AFAB) to inform future studies of doxycycline to protect against bacterial sexually transmitted infections (STIs).
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
09/30/2024
Locations: Hope Clinic, Atlanta, Georgia
Conditions: Sexually Transmitted Infection
Register for Updates